Todd Harris Sells 5,698 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 5,698 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38. Following the transaction, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Tyra Biosciences Price Performance

TYRA stock opened at $24.36 on Friday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -14.50 and a beta of 1.01. Tyra Biosciences, Inc. has a 1-year low of $10.38 and a 1-year high of $25.14. The business has a fifty day moving average price of $21.29 and a 200-day moving average price of $18.72.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, analysts anticipate that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its position in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares during the period. Wellington Management Group LLP boosted its stake in shares of Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after buying an additional 8,324 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after buying an additional 14,352 shares during the last quarter. HighVista Strategies LLC bought a new stake in shares of Tyra Biosciences in the second quarter worth $257,000. Finally, Victory Capital Management Inc. increased its position in Tyra Biosciences by 53.4% during the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock valued at $696,000 after acquiring an additional 17,490 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Oppenheimer raised their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday. Wedbush reissued an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Thursday, August 8th. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.